Ixchel On Last Legs With Antitrust Claims Against Biogen
By Bryan Koenig (January 26, 2018, 7:59 PM EST) -- A California federal judge on Thursday gave Ixchel Pharma LLC one last chance to accuse Biogen Inc. of entering into an anti-competitive agreement with another company and undermining Ixchel's development of a treatment for a rare neuromuscular disease, holding the latest complaint is just as deficient as its predecessor.
U.S. District Judge William B. Shubb said Ixchel has already twice amended its complaint, and he concluded that further amendments to its first four claims "would be futile." The only reason Judge Shubb allowed Ixchel a single additional bite at the apple, he said in dismissing the company's second amended complaint, is...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!